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Acute kidney injury (AKI) has been recognized as a risk factor
for the development of chronic kidney disease (CKD).
Aldosterone has a critical role in promoting renal injury
induced by ischemia. Here, we evaluated whether
spironolactone administered before or after AKI caused by
ischemia protects against CKD. In the first set of experiments,
Wistar rats underwent a sham operation without or with
prior spironolactone treatment, or underwent 45minutes
of bilateral renal ischemia without or with spironolactone
treatment before ischemia and assessed over 270 days. The
second set of rats received low (20mg/kg) or high (80mg/kg)
doses of spironolactone at three different times after the
sham operation or bilateral renal ischemia and were assessed
after 90 days. Untreated animals developed CKD following
ischemia-induced AKI as characterized by a progressive
increase in proteinuria, renal dysfunction, podocyte injury,
glomerular hypertrophy, and focal sclerosis. This was
associated with increased oxidative stress, an upregulation of
tumor growth factor (TGF)-b, followed by upregulation of the
TGF-b downstream effectors phospho-Smad3, collagen I,
fibronectin, and proinflammatory cytokines. Treatment with
spironolactone either before or after ischemia prevented
subsequent CKD by avoiding the activation of fibrotic and
inflammatory pathways. Thus, spironolactone may be a
promising treatment for the prevention of AKI-induced CKD.
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Ischemic kidney injury is the primary cause of acute kidney
injury (AKI) in hospitalized patients and is associated
with high morbidity and mortality rates. In addition, the
incidence of AKI has significantly increased in the past
15 years owing to an aging general population and the
increased prevalence of obesity, diabetes, and hypertension,
which predispose patients to an AKI event.1–5 AKI occurs
in approximately 15% of hospitalized patients and in up to
40–60% of intensive care unit patients.6,7
For many years, it was commonly thought that patients
surviving episodes of AKI recover their renal function without
further consequences. However, recent evidence based on
epidemiological observations in patients who suffer from
AKI strongly suggests otherwise. AKI has thus been proposed
to be a risk factor for developing chronic kidney disease
(CKD) and, in particular, for promoting the transition of
CKD to end-stage renal disease.8–11 In support of this hypo-
thesis, the probability of developing CKD or end-stage renal
disease over time is proportional to the severity and duration
of the AKI event.8,12,13 Moreover, of great concern is the
recent evidence demonstrating that 6.6% of AKI patients who
had a complete renal function recovery exhibited a greater
risk of death and de novo CKD after 2–4 years of follow-up.12
Until now, however, the progression of AKI to CKD in rats
with two intact kidneys, which would allow elucidating the
mechanisms causing AKI to progress to CKD, has been rarely
explored. Such a model would also be beneficial for identi-
fying pharmacological interventions to prevent injury due to
AKI and/or stop the development of CKD and end-stage
renal disease.
Several studies involving experimental models have demon-
strated that aldosterone has an important role in the
physiopathology of renal injury induced by ischemic process,
including acute and chronic cyclosporine A nephrotoxicity
and ischemia/reperfusion (I/R).14–21 Accordingly, we have
shown that prophylactic spironolactone treatment16 or adrenal
gland removal17 completely prevents AKI in rats undergoing
bilateral renal ischemia. Furthermore, spironolactone
administration at different postischemia intervals prevents or
reduces functional and structural renal injury,22 suggesting
that aldosterone is a key molecule in mediating ischemic renal
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injury and that mineralocorticoid receptor (MR) antagonism,
even after ischemia, is a helpful strategy to prevent AKI.
In this study, we characterized a model of CKD induced
by a single episode of ischemic AKI and the molecular
mechanisms that lead to the development of CKD. Our data
reveal that spironolactone administration before or after the
ischemic insult is a useful strategy to prevent or reduce the
development of CKD.
RESULTS
We have previously shown that, after 24 h of bilateral
ischemia, rats develop severe renal dysfunction and tubular
injury.16 Figure 1 shows that renal dysfunction induced by
ischemia was completely resolved after 9 days of reperfusion,
similar to conditions that often occur in clinical settings.
Urinary protein excretion was significantly elevated after 24 h
of reperfusion in rats subjected to ischemia and continues to
progressively decline until normal values were reached after
6 days of reperfusion (Figure 1a). Proteinuria in spirono-
lactone-pretreated rats was 50% lower than the proteinuria in
the untreated group, and normal levels were reached faster.
Consequently, the rats undergoing ischemia recovered renal
function after 10 days, as demonstrated by normal values of
renal blood flow, serum creatinine, and creatinine clearance
(Figure 1b–d). Despite the complete improvement in renal
function, interleukin (IL)-6 mRNA and phosphorylated Smad3
levels were significantly higher than those in the sham-
operated group. Cytokine upregulation was not observed in
spironolactone-pretreated rats (Figure 1e–f). These results
suggest that although renal function recovered, proinflam-
matory and profibrotic pathways remained active. These
pathways may be able to perpetuate renal injury, which can
lead to CKD, a situation that did not occur in spironolac-
tone-pretreated animals.
Ischemic insult leads to progressive renal dysfunction that
can be prevented with spironolactone pretreatment
We assessed whether an AKI episode induced by ischemia
leads to CKD. Because we have previously shown that I/R
injury is prevented by spironolactone pretreatment or adrenal
gland removal,16,17 we evaluated whether spironolactone
pretreatment before ischemia also prevents CKD develop-
ment. There was considerable mortality in the A-to-C group
in the first 10 days after ischemia (57%), and survival was
markedly improved by spironolactone pretreatment (15%)
(Figure 2a). Proteinuria was assessed every 30 days. The
animals that survived the ischemic insult developed a
progressive increase in proteinuria, from 20.2±1.5mg/day
at 30 days to 164.8±11.3mg/day at 270 days. This increase
was not observed in the A-to-Cþ Sp group (9.2±1.0mg/day
at 30 days and 27.1±2.0mg/day at 270 days) (Figure 2b).
Despite the similar body weights of all rats at the beginning
of the study, the A-to-C group exhibited a lower average body
weight at the end of the study (583±16.3 g) than did the S,
Sp, and A-to-Cþ Sp groups (752±28.3, 729±19.2, and
721±11.8 g, respectively). After 9 months, the A-to-C group
developed renal dysfunction that was characterized by a
significant reduction in renal blood flow and creatinine
clearance (Figure 2c and d). Interestingly, the A-to-Cþ Sp
group failed to develop renal dysfunction. As shown in
Figure 2e, at the end of the study, the mean arterial pressure
was similar among the groups. Therefore, the renal injury
observed in the rats that developed CKD was not due to
hypertension. In agreement with these findings, the rats that
developed CKD exhibited an increase in the levels of urinary
kidney injury molecule-1, an effect that was not observed in
the A-to-Cþ Sp group (Figure 2f).
Ischemic insult leads to severe renal structural injury:
prevention by spironolactone pretreatment
Representative light microscopy sections from rat kidneys
stained with periodic acid–Schiff are shown in Figure 3a–d.
R
en
al
 b
lo
od
 fl
ow
(m
l/m
in)
12
10
8
6
4
2
0
Cr
ea
tin
in
e 
cle
ar
a
n
ce
(m
l/m
in)
2.5
2.0
1.5
1.0
0.5
0.0
p-Smad3
Smad3
p-
Sm
ad
3/
Sm
ad
3
1.0
0.8
0.6
0.4
0.2
0.0
¥
60
40
20
0
*
*
*
1.0
0.8
0.6
0.4
0.2
0.0
IL
-6
/1
8S
12
8
4
0
Se
ru
m
 c
re
a
tin
in
e 
(m
g/d
l)
Days
1 3 6 9
Pr
ot
ei
nu
ria
 m
g/
24
 h
* *
Figure 1 | Renal dysfunction induced by ischemia was completely
resolved after 10 days of reperfusion, but proinflammatory and
profibrotic cytokines remained enhanced. (a) Urinary protein
excretion 1, 3, 6, and 9 days after reperfusion, in the sham (o),
bilateral renal ischemia (), and ischemiaþ Sp pretreatment ()
groups. At 10 days after reperfusion, the rats were killed, and renal
function was determined. (b) Mean renal blood flow, (c) serum
creatinine, and (d) creatinine clearance. (e) Interleukin (IL)-6 mRNA
levels were measured in the renal cortex. (f) The upper insets show
representative autoradiographs from the phosphorylated-Smad3
(p-Smad3) and Smad3 western blot analysis for sham (white bars),
bilateral renal ischemia (black bars), and ischemiaþ Sp pretreatment
(gray bars) groups. The lower graphs display the corresponding
densitometric analysis. *Po0.05 vs. the sham group and Po0.05 vs.
the ischemia group.
bas i c resea rch J Barrera-Chimal et al.: Spironolactone prevents CKD as a consequence of AKI
94 Kidney International (2012) 83, 93–103
Rats undergoing ischemia exhibited severe structural altera-
tions characterized by glomerular hypertrophy, glomerulo-
sclerosis, cast formation, severe tubular dilation, and
tubulointerstitial fibrosis. By contrast, the A-to-Cþ Sp group
exhibited glomerular and tubular architecture similar to that
of control rats. These findings were corroborated by
quantification of the number of dilated tubules, percentage
of glomerulosclerosis, and glomerular diameter size (Figures
3 and 4). Tubular dilation was present in 42.3±5.0% of the
total tubules in the A-to-C group, whereas only 13.1±2.7%
of the A-to-Cþ Sp group displayed dilation (Po0.01).
Similarly, the A-to-C group exhibited a significantly higher
glomerulosclerosis percentage (10.0±4.4%) than the S and
A-to-Cþ Sp groups (0% and 0.4±0.4%, respectively).
The degree of glomerular hypertrophy was evaluated by
measuring glomerulus diameter and by generating a
distribution of glomerular size. Figure 4a shows the normal
diameter distribution of the control group, wherein most of
the glomeruli were in the range of 101–125 mm (38.3%), and
only a minor proportion was found in the ranges of
76–100 mm (19.5%) and 126–150 mm (27.5%). The histogram
for the control group exhibits a typical bell-shaped Gaussian
distribution, as we have shown previously.21 By contrast, in
the A-to-C group, the glomerular diameter distribution was
shifted to the right, reflecting glomerular hypertrophy.
Accordingly, 43.3% of the glomeruli were 4151 mm in
diameter. In addition, a lower proportion of glomeruli
were found in the diameter ranges of 101–125 mm (20.4%),
76–100 mm (8.3%), and 50–75 mm (0%). All of these
differences were statistically significant according to con-
tingency analysis, as shown in Figure 4b. The glomerular size
distribution of the A-to-Cþ Sp group was similar to that of
the control group, but not to that of the A-to-C group
(Figure 4c), indicating that glomerular hypertrophy was
nearly absent. In agreement with these findings, renal
hypertrophy in the A-to-C group was also evidenced by a
significant elevation in the mean kidney weight (2.5±0.2 g)
compared with the S and Sp groups (1.6±0.1 and 1.6±0.1 g,
respectively); this increase was not observed in the A-to-
Cþ Sp group (1.5±0.1 g).
Transmission electron microscopy of rat kidneys with
CKD revealed ultrastructural alterations that included
microvillus degeneration and effacement and detachment
of podocyte foot processes (Figure 4e). These alterations
were rarely observed in the A-to-Cþ Sp group (Figure 4f).
Furthermore, an extensive tubulointerstitial area was affected
by fibrosis in the A-to-C group (Figure 5a and b), but a lower
extent of fibrosis was observed in the A-to-Cþ Sp group
(Figure 5c and d). These observations were confirmed by the
morphometric analysis represented in Figure 5e. The A-to-C
group exhibited fibrosis in 44.8±16.0% of the tubulointer-
stitial area, compared with 18.7±4.5% in the A-to-Cþ Sp
group; this difference was significant.
Tubular dilation is due in part to cellular proliferation
To determine whether the severe tubular dilation observed in
the A-to-C group was associated with tubular cell prolifera-
tion, immunohistochemical analysis of proliferating cell nuclear
antigen (PCNA) was performed. The A-to-C group exhibited
considerable tubular cell proliferation as demostrated by the
number of PCNAþ cells, an effect that was almost absent
in the A-to-Cþ Sp group (Figure 6a–c). These findings were
confirmed by calculating the percentage of nuclei that stained
positive for PCNA (Figure 6d). The positive cells were primarily
located in the dilated tubules, suggesting that enhanced cell
proliferation is promoting tubular dilation in the A-to-C
group. This assumption is also supported by a significant
correlation between the percentage of dilated tubules and the
percentage of PCNAþ cells (Figure 6e, r2¼ 0.87).
Tubulointerstitial fibrosis is mediated by TGF-b pathway
activation
The role of the tumor growth factor (TGF)-b pathway
in promoting tubulointerstitial fibrosis was also evaluated.
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Figure 2 | Acute kidney injury leads to the development of
chronic kidney disease (CKD), which can be prevented by
spironolactone pretreatment. Four groups were included: sham
surgery (S), n¼ 9; rats receiving spironolactone 3 days before sham
surgery (20mg/kg per day), n¼ 9 (Sp); rats undergoing renal bilateral
ischemia, n¼ 28 (A-to-C); and rats receiving spironolactone 3 days
before bilateral ischemia, n¼ 13 (A-to-Cþ Sp). (a) The survival rate in
the A-to-C group (black circles) was 43%, compared with 85% in the
A-to-Cþ Sp group (gray circles) and 100% in the sham and Sp group
(overlaid white circles). (b) Urinary protein excretion was measured
every 30 days during follow-up: sham (r), Sp (D), A-to-C (), and A-to-
Cþ Sp (o). At the end of the experimental period, (c) renal blood flow,
(d) creatinine clearance, (e) mean arterial pressure, and (f) urinary
kidney injury molecule-1 (Kim-1) levels were determined in the sham
(white bars), Sp (white bars), A-to-C (black bars), and A-to-Cþ Sp
groups (gray bars). *Po0.05 vs. the S and Sp groups.
Kidney International (2012) 83, 93–103 95
J Barrera-Chimal et al.: Spironolactone prevents CKD as a consequence of AKI bas i c resea rch
The A-to-C group exhibited a significant twofold elevation in
TGF-b mRNA levels. This increase was not observed in the
A-to-Cþ Sp group (Figure 7a). To assess whether this
pathway was efficiently activated, the renal levels of down-
stream effectors of the TGF-b pathway, including phos-
phorylated Smad3, fibronectin, collagen I, and a-smooth
muscle actin (a-SMA), were measured by western blot
analysis as shown in Figure 7b–f. The levels of all of these
proteins were significantly elevated in the rats that developed
CKD. Intriguingly, the activation of the TGF-b pathway was
completely prevented in the A-to-Cþ Sp group. Recent
studies have shown that when Smad2 is phosphorylated, it
can act as an antifibrotic modulator of the TGF-b pathway.23
We found that the A-to-Cþ Sp group, which exhibited
less tubulointerstitial fibrosis, also displayed a significant
elevation in phospho-Smad2 levels.
Renal injury induced by an ischemic insult is also mediated
by increased oxidative stress
Urinary H2O2 excretion in the A-to-C group was significantly
elevated compared with the S and Sp groups (64.1±7.5 vs.
10.4±1.1 and 5.9±1.0 nmol/min, respectively) (Figure 8a).
However, the elevation in urinary H2O2 excretion was abrogated
in the A-to-Cþ Sp group (14.8±2.5 nmol/min). In addition,
catalase activity was significantly reduced in the A-to-C group
(Figure 8b), and this effect was almost entirely prevented in the
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Figure 4 | Glomerular hypertrophy and ultrastructural lesions in rats with chronic kidney disease (CKD). (a) The glomerular diameter
distribution is represented in white bars for the sham group, (b) in black bars for the A-to-C group, and (c) in gray bars for the A-to-Cþ Sp
group. Representative transmission electron micrographs are shown in (d) the sham group, (e) the A-to-C group, and (f) the A-to-Cþ Sp group.
Black arrows indicate foot process fusion, and asterisks indicate foot process detachment. Original magnification: 6,300. *Po0.05 vs. the S
group and Po0.05 vs. the A-to-C group.
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Figure 3 | An acute kidney injury (AKI) episode leads to severe structural damage, which can be prevented by Sp pretreatment.
(a, b) Representative images of periodic acid–Schiff (PAS)-stained sections from the A-to-C group, and (c, d) sections from the A-to-Cþ Sp
group. (e) The percentage of dilated tubules was quantified by counting the number of dilated tubules as a proportion of the total number of
tubules. (f) Glomerulosclerosis percentage for the sham (white bars), Sp (second set of white bars), A-to-C (black bars), and A-to-Cþ Sp groups
(gray bars). *Po0.05 vs. the S and Sp groups.
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A-to-Cþ Sp group. No differences in glutathione peroxidase
activity were observed among the groups (Figure 8c).
Inflammatory cytokine upregulation is involved in
ischemia-induced CKD
Tumor necrosis factor alpha (TNF-a), monocyte chemotactic
protein-1 (MCP-1), and IL-6 mRNA and protein levels were
assessed by real-time reverse transcription–polymerase chain
reaction and enzyme-linked immunosorbent assay, respec-
tively. As shown in Figure 9, the mRNA levels of these
cytokines were upregulated in the A-to-C group by 1.6-fold
for TNF-a and more than 13-fold for MCP-1 and IL-6,
compared with the S group. By contrast, the A-to-Cþ Sp
group exhibited mRNA levels similar to the control group.
These observations were corroborated at the protein level; a
similar pattern was observed in the enzyme-linked immu-
nosorbent assay results.
CKD induced by AKI was also reduced by spironolactone
administration after the ischemic insult
Spironolactone administered at 0 or 1.5 h after the ischemic
insult prevented the development of proteinuria compared
with the untreated A-to-C group either at low or high doses
(Figure 10a and d). A low dose of spironolactone adminis-
tered 3 h after ischemia was unable to prevent, but did
significantly reduce, the progressive elevation of proteinuria
(Figure 10a). These findings were not associated with
significant changes in renal blood flow (Figure 10b and e)
or creatinine clearance (Figure 10c and f), probably because
3 months is an early stage of the CKD, often exhibiting
proteinuria, without renal dysfunction, as was observed after
a longer period of observation after similar ischemia
(Figure 2). Despite the lack of significant differences among
these groups, spironolactone-treated animals exhibited better
renal function than the ischemic group.
At 3 months after inducing bilateral renal ischemia, the
untreated A-to-C group, compared with the sham-operated
group, exhibited morphological alterations, such as tubular
dilation, cast formation, glomerular hypertrophy, and
extensive tubulointerstitial fibrosis (Supplementary Figure
S1 online). All of these changes were reduced in the animals
treated with a low dose of spironolactone (Supplementary
Figure S2 online) and were prevented in animals treated with
a high dose of spironolactone (Supplementary Figure S3
online). In fact, glomerular hypertrophy (measured as the
distribution of glomerular diameters) was prevented in the
groups that received a low dose of spironolactone at 0 h
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Figure 5 | Tubulointerstitial fibrosis in rats with chronic kidney
disease (CKD). (a, b) Representative light micrographs after Sirius red
staining showing the presence of fibrosis (in red) from the A-to-C
group, and (c, d) micrographs from the A-to-Cþ Sp group. (e) The
percentage of tubulointerstitial fibrosis in each of the four groups at
the end of the 270-day experiment was quantified by morphometric
analysis for sham (white bars), Sp (second set of white bars), A-to-C
(black bars), and A-to-Cþ Sp groups (gray bars). *Po0.05 vs. the S
and Sp groups.
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Figure 6 | Tubular cell proliferation as assessed by proliferating
cell nuclear antigen (PCNA) immunohistochemistry. To evaluate
whether epithelial cells were proliferating and provoking tubule
dilation, immunohistochemistry for PCNA was performed in kidney
sections from the four groups. (a) Representative images from the
sham, (b) A-to-C, and (c) A-to-Cþ Sp groups. (d) The percentage of
PCNAþ cells in the sham (white bars), Sp (second set of white bars),
A-to-C (black bars), and A-to-Cþ Sp groups (gray bars). (e) The
correlation between the percentage of PCNAþ cells and the
percentage of dilated tubules (r2¼ 0.87). *Po0.05 vs. the S and Sp
groups, and Po0.05 vs. the A-to-C group.
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(Figure 11c) or high dose at either 0 or 1.5 h after renal
bilateral ischemia (Figure 11f and g, respectively). Although
kidney changes were not completely prevented, these
renoprotective effects of spironolactone were also observed
with a low dose at 1.5 and 3 h after ischemia (Figure 11d and
e, respectively). Morphometric analyses demonstrated that, 3
months after inducing ischemia, the untreated rats exhibited
fibrotic damage in 33.3% of their tubulointerstitium
compared with damage in 3.7% of the tubulointerstitium
in the sham-operated rats (Supplementary Figure S1 online).
In contrast, a low dose of spironolactone administered either
at 0 and 1.5 h post ischemia reduced the tubulointerstitial
fibrosis to 14.8% and 15.1%, respectively, and the 3-h
administration reduced the fibrosis to a lesser extent, 20.9%
(Supplementary Figure S2 online). A high dose of spirono-
lactone at 0 or 1.5 h post ischemia was more effective in
reducing the area affected by tubulointerstitial fibrosis to
11.8% and 7.8%, respectively (Supplementary Figure S3
online).
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and (f) IL-6 protein levels quantified by enzyme-linked
immunosorbent assay (ELISA) in tissue kidney homogenates.
*Po0.05 vs. the S and Sp groups.
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Molecular markers of renal fibrosis and inflammation
also provided evidence of the protection conferred by
spironolactone. The upregulation of TGF-b mRNA levels
was prevented or reduced by a low or high dose of spirono-
lactone administered at 0 or 1.5 h after ischemia (Figure 12a
and e). However, increased phospho-Smad3 levels remained
elevated in rats treated with a low dose, but not with a
high dose, of spironolactone (Figure 12b and f). The
renoprotective effect of spironolactone was also associated
with the prevention of a-SMA and MCP-1 upregulation
(Figure 12c–h).
DISCUSSION
In this study, we characterized a rat model of CKD induced
by a single episode of AKI. We observed that an episode of
AKI was resolved in surviving animals within a period of 10
days. However, although physiological parameters returned
to normal values, activation of proinflammatory and
profibrotic signals persisted. During the following months,
progressive deterioration of renal function and renal
structures was observed in rats surviving AKI, leading to
the development of CKD. Thus, this model resembles what is
currently believed to occur in the clinical setting.11–13,24–27
Patients who survive an episode of AKI and apparently
recover renal function may develop CKD later in life.8,24 In
this study, we observed that spironolactone administration
before or after the ischemic insult prevented or significantly
diminished the severity of an AKI episode, without signs of
proinflammatory or profibrotic activation after 10 days
of ischemia. Thus, spironolactone pretreatment resulted in
a reduction in rat mortality and in the prevention of
CKD. These observations demonstrate the relevance of the
prevention of AKI episodes to a reduction in the prevalence
of CKD.
CKD development in rats surviving AKI was characterized
by a progressive increase in urinary protein excretion, renal
dysfunction, glomerular hypertrophy, severe tubular dilation,
tubulointerstitial fibrosis, and podocyte injury. Our study
supports the hypothesis that an ischemic insult is sufficient to
lead to progressive CKD in the rat, despite apparent recovery
from the AKI episode. Because it was possible that CKD
resulted from irreversible renal artery damage caused by the
clamping, a group of rats was studied after 10 days of
ischemia, confirming that this was not the case. After 10 days,
renal function returned to normal values. Although renal
histopathology was not analyzed at this point, we have
previously reported that after 3 days of I/R, the tubular
epithelium had almost recovered its normal structure.28,29
However, in this study, we found that profibrotic and
inflammatory cytokines remained at high levels despite a
return to normal renal function values. In addition,
cytokines such as TNF-a and IL-1b, IL-6, IL-12, IL-15, IL-
18, and IL-32 are known to be induced as a result of the
enhanced leukocyte activation and leukocyte–endothelial
adhesion observed after I/R. Moreover, the renal tubular
epithelium may generate proinflammatory cytokines such as
TNF-a, IL-6, IL-1b, and TGF-b.30–33 It is important to note
that Basile et al.34,35 and Ho¨rbelt et al.36 have demonstrated a
persistent reduction in vascular density after I/R that main-
tains a continuous hypoxic and inflammatory state. Further-
more, Conger et al.37 demonstrated that the postischemic
kidney does not properly autoregulate the blood flow.
All of these adverse conditions perpetuate continuous
cycles of hypoxic damage and inflammation that injure
the surrounding tissues and eventually lead to CKD, as has
been clearly discussed by Bedfoord et al.38 In agreement
with all these findings, we found that, after 9 months,
the rats that developed CKD exhibited greater levels of
the proinflammatory cytokines compared with the rats
that were pretreated with spironolactone. Interestingly,
MCP-1 upregulation observed 3 months after ischemia was
also prevented when spironolactone was administered
after the insult. Our results suggest that the beneficial
results of spironolactone in preventing chronic inflammation
are a result of its ability to attenuate I/R-induced acute
inflammation.
The CKD induced by an AKI episode was characterized by
a progressive enhancement in urinary protein excretion and
renal dysfunction without changes in mean arterial pressure.
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Figure 10 | Spironolactone administration after the ischemic
insult prevents the development of proteinuria. (a) Urinary
protein excretion at 1, 30, 60, and 90 days in sham (white circles), in
A-to-C (black circles), and in rats receiving Sp (20mg/kg) at 0, 1.5,
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ischemia. After 90 days of follow-up, (b, e) renal blood flow and
(c, f) creatinine clearance were determined in the sham group
(white bars), A-to-C group (black bars), and the groups receiving a
low dose of Sp (gray bars) at 0, 1.5, or 3 h after ischemia or a high
dose of Sp (dark gray bars) at 0 or 1.5 h after bilateral ischemia.
*Po0.05 vs. sham-operated rats.
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These conditions provide us with an experimental model that
dissects the detrimental effect of an AKI episode on renal
function and structure without changes in blood pressure.
Accordingly, the animals that suffered CKD exhibited severe
structural injury. Glomerular hypertrophy and glomerulo-
sclerosis were observed 9 months after inducing ischemia.
These alterations were also associated with ultrastructural
changes. It is plausible that this glomerular injury is a
consequence of the endothelial injury and the endothelial-to-
mesenchymal transition that occurred after the ischemia.34,35
Interestingly, in this study, we found that spironolactone
administration both before and after renal ischemia
prevented the transition of AKI to CKD.
Aldosterone binding to the MR has been suggested to
influence endothelial function and vascular tone.17,19,39,40
Supporting this finding, mice overexpressing MR in the
endothelium exhibit altered vascular tone,40 and aortic wall
thickness has been reported in patients with primary hyper-
aldosteronism.41 Consistent with this result, aldosterone
infusion in mice reduces the expression of glucose-6-phos-
phate dehydrogenase (G6PDH), a key enzyme in maintaining
the balance between nitric oxide and reactive oxygen species
production.42 Therefore, aldosterone has been proposed as a
risk factor of vascular injury.43 The mechanisms involved,
however, have not been clearly elucidated. In this regard, we
have previously demonstrated that MR antagonism precludes
the characteristic hypoperfusion and oxidative stress induced
by I/R, suggesting that aldosterone has a pivotal role in
mediating renal dysfunction.16,22 It is possible that the
endothelium and the renal plasma flow of spironolactone-
treated rats in this study was minimally affected as a
consequence of the I/R injury; therefore, the glomerular
structure remained unaffected in the long term.
Tubulointerstitial fibrosis is a common feature of CKD
progression (for a review, see Rodriguez-Iturbe and Gar-
cia44). In fact, severe tubular dilation and an extensive area
affected by tubulointerstitial fibrosis were found in the A-to-
C group. These results suggest that the tubulointerstitium
is more susceptible to the effects of an AKI episode and
contributes to the progression and severity of CKD in rats
suffering from AKI. Accordingly, the severity of tubular
damage reportedly exhibits a more significant correlation
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with the reduction in creatinine clearance than with
glomerular injury scores.45,46 These tubular defects were
associated with an increase in tubular cell proliferation, as
demonstrated by the significant increase in PCNAþ staining
and by the strong correlation with tubular dilation
(r2¼ 0.87). In this study, however, the location of PCNAþ
cells in the epithelium of the dilated tubules strongly suggests
that the tubular dilation observed in the A-to-C group was
mediated in part by uncontrolled tubular cell proliferation
triggered during the regeneration process after the ischemic
insult. Although a previous study proposed that the increase
in cellular proliferation is a necessary process to regenerate
tubular epithelium in a period that typically is completed
within 4 weeks after ischemia,47 recent evidence demon-
strated that ischemic, nephrotoxic, and obstructive injuries to
the kidney induce a G2/M cell cycle arrest in the proximal
tubular epithelial cells, sustaining proliferation indefinitely.48
In this regard, Wynn49 has proposed that this cell cycle arrest
converts normal epithelial cells to a phenotype that promotes
the growth and activation of fibroblasts, turning-on the
fibrotic process after an ischemic insult. In addition, TGF-b
has been recognized as a key mediator of the genesis of renal
fibrosis.32,50 TGF-b also contributes to the fibrogenesis
through inducing epigenetic modifications in fibroblasts
in a process that includes the hypermethylation of the
gene encoding RASAL1 by the methyltransferase Dnmt1.51
Accordingly, we found that tubulointerstitial fibrosis
developed in the A-to-C group and was associated with
increased expression and activation of TGF-b, as evidenced
by increases in phospho-Smad3 and its target ECM proteins.
Interestingly, activation of the TGF-b signaling pathway was
not observed in the animals treated with spironolactone
before or after (high dose) ischemia. These data highlight the
contribution of TGF-b in mediating renal fibrosis after an
ischemic insult. Although Smad2 and Smad3 interact and
mediate TGF-b signaling, one recent line of evidence has
shown that phospho-Smad2 may act as an antifibrotic
effector of the TGF-b pathway.23 In agreement with those
results, the renoprotection conferred by spironolactone was
associated with increased levels of phospho-Smad2.
The epithelial-to-mesenchymal transition has been sug-
gested to promote tubulointerstitial fibrosis.52,53 Under
pathological conditions, tubular cells may dedifferentiate
into myofibroblasts. TGF-b appears to promote this process
by activating the Smad, ILK, and ERK pathways, as observed
in tubular cells.53 To monitor epithelial-to-mesenchymal
transition, a-SMA protein levels were measured in the
kidney. As expected, the renal fibrosis observed in the A-to-
C group was associated with increased a-SMA protein levels.
CKD progression has also been linked to an imbalance
in free-radical production and antioxidant defense.44,54
We confirmed that the rats that developed CKD exhibited
greater urinary H2O2 excretion and a reduction in catalase
activity. These changes in a-SMA levels and antioxidant
factors were not observed in the A-to-Cþ Sp group.
In summary, we characterized an experimental model
of CKD induced by AKI in the rat. Several mechanisms
were responsible for CKD development, including increased
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Figure 12 | Tumor growth factor (TGF)-b and inflammation pathways in rats treated with spironolactone after the ischemic insult.
(a, e) TGF-b mRNA levels quantified by real-time reverse transcription–polymerase chain reaction (RT-PCR). Densitometric analysis of the
western blots performed for (b, f) p-Smad3 and (c, g) a-SMA. (d, h) MCP-1 protein levels quantified in renal tissue by enzyme-linked
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tubular cell proliferation, increased TGF-b pathway activa-
tion and oxidative stress, and overexpression of proinflam-
matory cytokines. By using this model of CKD, we
demonstrated that the prevention of AKI with spironolactone
completely prevents the progression to CKD. Moreover, we
also demonstrate that administering an MR blocker after the
ischemic insult also prevented CKD. Our results suggest
that the treatment of patients with spironolactone after an
AKI episode could be of help in preventing the development
of CKD.
MATERIALS AND METHODS
All experiments involving animals were conducted in accordance
with the Guide for the Care and Use of Laboratory Animals (National
Academy Press, Washington, DC, 1996) and were approved by the
Animal Care and Use Committee at our Institution.
Protocol 1
In all, 62 male Wistar (weighing 270–300 g) rats were divided into
four groups: (1) rats subjected to sham surgery, n¼ 9 (S); (2) rats
treated with spironolactone at 20mg/kg per day by gastric gavage
3 days before sham surgery, n¼ 9 (Sp); (3) rats undergoing bilateral
ischemia for 45min, n¼ 28 (A-to-C); and (4) rats that received
spironolactone 3 days before bilateral ischemia, n¼ 13 (A-to-Cþ
Sp). All animals were observed for 9 months. In addition, four rats
from the S, A-to-C, and A-to-Cþ Sp groups were included and
observed for 10 days. All animals were kept in a 12:12 h day–night
cycle and with free access to water and food.
Protocol 2
Because we recently demonstrated that postischemia MR blockade is
beneficial in the prevention of AKI, with the best renoprotection
observed in the first 3 h after ischemia,22 this set of experiments
was designed to evaluate whether postischemia spironolactone
administration confers protection against the development of CKD.
In all, 33 male Wistar (270–315 g) rats were divided into seven
groups: sham-operated rats (S); rats subjected to bilateral renal
ischemia for 45min (A–C); and five groups of rats that underwent
bilateral renal ischemia for 45min, but also received one dose of
spironolactone at 20mg/kg by gastric gavage at 0, 1.5, or 3 h after
ischemia (A-to-C, 0 h; A-to-C, 1.5 h; and A-to-C, 3 h, respectively),
or that received a higher dose of spironolactone (80mg/kg) at 0 or
1.5 h after ischemia (A-to-C 80, 0 h and A-to-C 80, 1.5 h). These
animals were followed up for 3 months.
All other methods are described in the Supplementary Materials
online.
Statistical analysis
The results are presented as the mean±s.e. The significance of the
differences between the groups was assessed by analysis of variance
(ANOVA) using the Bonferroni correction for multiple compar-
isons. All of the comparisons passed the normality test. The
differences in the ranks of glomerular diameters among the groups
were evaluated by contingency analysis, and the differences were
assessed using the w2 test with the Yates correction. Statistical
significance was defined as P–value o0.05.
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